Drug Trial Radar · NCT06906341
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
270
Planned (sponsor's estimate)
Start
Apr 11, 2025
Primary completion
Dec 2027
Study completion Aug 2028
Sponsor
- Lead sponsor
- Corcept TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Apr 2, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 2, open-label, global, multi-arm study to evaluate efficacy and safety of relacorilant in combination with other treatments in patients with gynecological cancers.
Conditions
- Ovarian Cancer
- Fallopian Tube Cancer
- Peritoneal Neoplasms
- Endometrial Cancer
Interventions
Relacorilant 150 mg once daily (QD)Drug
Relacorilant is administered under fed conditions as capsules for oral dosing on the day before, the day of, and the day after nab-paclitaxel infusion.
Nab-paclitaxel 80 mg/m^2Drug
Nab-paclitaxel is administered as IV infusion on Days 1, 8, and 15 of each 28-day cycle.
Bevacizumab 10 mg/kgDrug
Bevacizumab is administered as IV infusion on Days 1 and 15.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free Survival (PFS)Time frame: Date of first dose until PD or death, up to 18 months
Locations
53 sites in 8 countries. Site status is shown where the registry gives one.
004
Birmingham, Alabama · Recruiting
150
Palo Alto, California · Recruiting
278
San Francisco, California · Recruiting
014
San Francisco, California · Recruiting
032
Aurora, Colorado · Recruiting
544
Fort Myers, Florida · Recruiting
335
Miami Beach, Florida · Recruiting
543
West Palm Beach, Florida · Recruiting
001
Chicago, Illinois · Recruiting
518
Minneapolis, Minnesota · Recruiting
334
Kansas City, Missouri · Recruiting
521
St Louis, Missouri · Recruiting
292
Albuquerque, New Mexico · Recruiting
304
Centerville, Ohio · Recruiting
517
Eugene, Oregon · Recruiting
127
Pittsburgh, Pennsylvania · Recruiting
522
Fairfax, Virginia · Recruiting
300
Norfolk, Virginia · Recruiting
121
Milwaukee, Wisconsin · Recruiting
109
Brussels, Belgium · Recruiting
326
Charleroi, Belgium · Recruiting
325
Hasselt, Belgium · Recruiting
108
Leuven, Belgium · Recruiting
328
Aalst, Belgium, Belgium · Recruiting
306
Lille, France · Recruiting
307
Nancy, France · Recruiting
310
Nice, France · Recruiting
324
Pierre-Bénite, France · Recruiting
323
Plérin, France · Recruiting
308
Toulouse, France · Recruiting
519
Aachen, Germany · Recruiting
255
Berlin, Germany · Recruiting
520
Kempten, Germany · Recruiting
321
Catania, Italy · Recruiting
122
Milan, Italy · Recruiting
516
Milan, Italy · Recruiting
295
Pavia, Italy · Recruiting
124
Rome, Italy · Recruiting
293
Torino, Italy · Recruiting
319
Treviso, Italy · Recruiting
Showing 40 of 53 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.